Synonyms: 1-[3,5-Bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)-3-piperidinecarboxamide; 1-[3,5-Bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)piperidine-3-carboxamide; CCG 100602; CCG100602
Molecular Formula: C21H17ClF6N2O2
Molecular Weight: 478.82
Linear Structural Formula: C21H17ClF6N2O2
Purity: >=98% (HPLC)
Storage: -20C
Biochem Physiol Actions: CCG-100602 is a CCG-1423 analog with significantly less cytotoxicity (0/14% WST-1 inhibition by 10/100 muM CCG-100602 vs. 44% by 10 muM CCG-1423) and similar efficacy against Rho/MKL1/SRF pathway-mediated transcription (by 78% with 100 muM CCG-100602 vs. 74% with 10 muM CCG-1423; IC50 = 9.8 muM/CCG-100602 vs. 1.5 muM/CCG-1423; by PC-3 SRE-luciferase assay), albeit at a reduced potency. CCG-100602 reduces the stiffening of spontaneously hypertensive rats (SHR) derived aortic VSMCs (1.12 muM) by inhibiting SRF/myocardin interaction and abrogates the increased aortic wall stiffness in SHR rats in vivo (7.5 mg/kg/d via s.c. osmotic pumps for 2 wks).